Core Viewpoint - The company, Jiuzhoutong, reported a significant growth in its traditional Chinese medicine segment, with a sales revenue of 2.83 billion yuan in the first half of 2025, marking a year-on-year increase of 19.05% [1] Group 1: Financial Performance - In the first half of 2025, the traditional Chinese medicine segment achieved a sales revenue of 2.83 billion yuan, including 1.22 billion yuan from self-produced medicinal slices, which represents a year-on-year growth of 13.16% [1] Group 2: Business Development - Jiuxin Chinese Medicine Group, a subsidiary, focuses on the development of authentic medicinal materials and medicinal slices, aiming to cover the entire industry chain of traditional Chinese medicine [2] - The company offers a diverse range of products under various brands, including ordinary slices, refined slices, directly consumable slices, toxic slices, and health foods, catering to market demands [2] - The OTC business features both refined and ordinary medicinal slices, with the refined slices covering 100 varieties and 300 specifications, while ordinary slices encompass 480 varieties and 1,500 specifications [2] Group 3: Brand and Product Strategy - Jiuxin Chinese Medicine has initiated a brand strategy overhaul and strategic expansion of product categories, focusing on the core concept of "Authentic Medicine Made by Jiuxin" [3] - The company aims to enhance its brand core competitiveness and market penetration by developing core flagship products and expanding into health-related products [3]